AST 0 3 0 3 B-clinical_variable
( 4 5 4 5 I-clinical_variable
SGOT)/ALT 5 14 5 14 I-clinical_variable
( 15 16 15 16 I-clinical_variable
SGPT 16 20 16 20 I-clinical_variable
) 20 21 20 21 I-clinical_variable
< 22 23 22 23 O
2.5 24 27 24 27 B-upper_bound
X 28 29 28 29 I-upper_bound
institutional 30 43 30 43 I-upper_bound
upper 44 49 44 49 I-upper_bound
limit 50 55 50 55 I-upper_bound
of 56 58 56 58 I-upper_bound
normal 59 65 59 65 I-upper_bound
unless 66 72 66 72 O
it 73 75 73 75 O
is 76 78 76 78 O
related 79 86 79 86 O
to 87 89 87 89 O
involvement 90 101 90 101 O
by 102 104 102 104 O
LCH 105 108 105 108 B-chronic_disease

Absolute 0 8 109 117 B-clinical_variable
neutrophil 9 19 118 128 I-clinical_variable
count 20 25 129 134 I-clinical_variable
≥ 26 27 135 136 O
750 28 31 137 140 B-lower_bound
cells/µL 32 40 141 149 I-lower_bound

Adult 0 5 150 155 O
Population 6 16 156 166 O
( 17 18 167 168 O
patients 18 26 168 176 O
> 27 28 177 178 O
= 28 29 178 179 O
18 30 32 180 182 B-lower_bound
years 33 38 183 188 I-lower_bound
): 38 40 188 190 O
Serum 41 46 191 196 B-clinical_variable
creatinine 47 57 197 207 I-clinical_variable
less 58 62 208 212 O
than 63 67 213 217 O
or 68 70 218 220 O
equal 71 76 221 226 O
to 77 79 227 229 O
1.0 80 83 230 233 B-upper_bound
mg 84 86 234 236 I-upper_bound
/ 86 87 236 237 I-upper_bound
dL 87 89 237 239 I-upper_bound

Alkaline 0 8 240 248 B-clinical_variable
phosphatase 9 20 249 260 I-clinical_variable
≤ 21 22 261 262 O
2.5 23 26 263 266 B-upper_bound
x 27 28 267 268 I-upper_bound
institutional 29 42 269 282 I-upper_bound
upper 43 48 283 288 I-upper_bound
limit 49 54 289 294 I-upper_bound
of 55 57 295 297 I-upper_bound
normal 58 64 298 304 I-upper_bound

Clofarabine 0 11 305 316 B-treatment
is 12 14 317 319 O
excreted 15 23 320 328 O
primarily 24 33 329 338 O
by 34 36 339 341 O
the 37 40 342 345 O
kidneys 41 48 346 353 O
. 48 49 353 354 O
Therefore 50 59 355 364 O
, 59 60 364 365 O
drugs 61 66 366 371 O
with 67 71 372 376 O
known 72 77 377 382 O
renal 78 83 383 388 O
toxicity 84 92 389 397 O
( 93 94 398 399 O
e.g.vancomycin 94 108 399 413 O
, 108 109 413 414 O
amphotericin 110 122 415 427 B-treatment
B 123 124 428 429 I-treatment
, 124 125 429 430 O
acyclovir 126 135 431 440 B-treatment
, 135 136 440 441 O
cyclosporin 137 148 442 453 B-treatment
, 148 149 453 454 O
methotrexate 150 162 455 467 B-treatment
, 162 163 467 468 O
tacrolimus 164 174 469 479 B-treatment
) 174 175 479 480 O
should 176 182 481 487 O
be 183 185 488 490 O
avoided 186 193 491 498 O
to 194 196 499 501 O
the 197 200 502 505 O
extent 201 207 506 512 O
possible 208 216 513 521 O
during 217 223 522 528 O
the 224 227 529 532 O
5 228 229 533 534 B-upper_bound
days 230 234 535 539 I-upper_bound
of 235 237 540 542 O
clofarabine 238 249 543 554 B-treatment
treatment 250 259 555 564 I-treatment
in 260 262 565 567 O
each 263 267 568 572 O
cycle 268 273 573 578 O
or 274 276 579 581 O
, 276 277 581 582 O
if 278 280 583 585 O
required 281 289 586 594 O
, 289 290 594 595 O
administered 291 303 596 608 O
cautiously 304 314 609 619 O
and 315 318 620 623 O
with 319 323 624 628 O
close 324 329 629 634 O
monitoring 330 340 635 645 O

Female 0 6 646 652 B-gender
patients 7 15 653 661 I-gender
of 16 18 662 664 O
childbearing 19 31 665 677 O
potential 32 41 678 687 O
must 42 46 688 692 O
have 47 51 693 697 O
a 52 53 698 699 O
negative 54 62 700 708 B-pregnancy
serum 63 68 709 714 I-pregnancy
pregnancy 69 78 715 724 I-pregnancy
test 79 83 725 729 O
within 84 90 730 736 O
14 91 93 737 739 B-upper_bound
days 94 98 740 744 I-upper_bound
prior 99 104 745 750 I-upper_bound
to 105 107 751 753 O
enrollment 108 118 754 764 O
. 118 119 764 765 O
Male 120 124 766 770 B-gender
and 125 128 771 774 O
female 129 135 775 781 B-gender
patients 136 144 782 790 I-gender
must 145 149 791 795 O
use 150 153 796 799 B-contraception_consent
an 154 156 800 802 I-contraception_consent
effective 157 166 803 812 I-contraception_consent
contraceptive 167 180 813 826 I-contraception_consent
method 181 187 827 833 I-contraception_consent
during 188 194 834 840 O
the 195 198 841 844 O
study 199 204 845 850 O
and 205 208 851 854 O
for 209 212 855 858 O
a 213 214 859 860 O
minimum 215 222 861 868 O
of 223 225 869 871 O
6 226 227 872 873 B-lower_bound
months 228 234 874 880 I-lower_bound
after 235 240 881 886 O
study 241 246 887 892 O
treatment 247 256 893 902 B-treatment

In 0 2 903 905 O
stratum 3 10 906 913 O
1 11 12 914 915 O
, 12 13 915 916 O
patients 14 22 917 925 O
must 23 27 926 930 O
have 28 32 931 935 O
failed 33 39 936 942 O
one 40 43 943 946 O
prior 44 49 947 952 B-treatment
systemic 50 58 953 961 I-treatment
chemotherapy 59 71 962 974 I-treatment
regimen 72 79 975 982 I-treatment
. 79 80 982 983 O
In 81 83 984 986 O
stratum 84 91 987 994 O
2 92 93 995 996 O
, 93 94 996 997 O
RDD 95 98 998 1001 B-chronic_disease
patients 99 107 1002 1010 O
must 108 112 1011 1015 O
have 113 117 1016 1020 O
failed 118 124 1021 1027 O
treatment 125 134 1028 1037 B-treatment
with 135 139 1038 1042 O
corticosteroid 140 154 1043 1057 B-treatment
. 154 155 1057 1058 O
ECD 156 159 1059 1062 B-chronic_disease
patients 160 168 1063 1071 O
who 169 172 1072 1075 O
have 173 177 1076 1080 O
confirmed 178 187 1081 1090 O
BRAF 188 192 1091 1095 O
V600E 193 198 1096 1101 O
mutation 199 207 1102 1110 O
must 208 212 1111 1115 O
have 213 217 1116 1120 O
failed 218 224 1121 1127 O
treatment 225 234 1128 1137 B-treatment
with 235 239 1138 1142 I-treatment
a 240 241 1143 1144 I-treatment
BRAF 242 246 1145 1149 I-treatment
inhibitor 247 256 1150 1159 I-treatment
or 257 259 1160 1162 O
are 260 263 1163 1166 O
not 264 267 1167 1170 O
considered 268 278 1171 1181 O
to 279 281 1182 1184 O
be 282 284 1185 1187 O
eligible 285 293 1188 1196 O
for 294 297 1197 1200 O
such 298 302 1201 1205 O
treatment 303 312 1206 1215 O

Individuals 0 11 1216 1227 O
who 12 15 1228 1231 O
are 16 19 1232 1235 O
known 20 25 1236 1241 O
to 26 28 1242 1244 O
be 29 31 1245 1247 O
HIV 32 35 1248 1251 B-chronic_disease
- 35 36 1251 1252 O
positive 36 44 1252 1260 O
on 45 47 1261 1263 O
combination 48 59 1264 1275 B-treatment
antiretroviral 60 74 1276 1290 I-treatment
therapy 75 82 1291 1298 I-treatment
are 83 86 1299 1302 O
ineligible 87 97 1303 1313 O
because 98 105 1314 1321 O
of 106 108 1322 1324 O
the 109 112 1325 1328 O
potential 113 122 1329 1338 O
for 123 126 1339 1342 O
pharmacokinetic 127 142 1343 1358 O
interactions 143 155 1359 1371 O
with 156 160 1372 1376 O
clofarabine 161 172 1377 1388 B-treatment
. 172 173 1388 1389 O
In 174 176 1390 1392 O
addition 177 185 1393 1401 O
, 185 186 1401 1402 O
these 187 192 1403 1408 O
individuals 193 204 1409 1420 O
are 205 208 1421 1424 O
at 209 211 1425 1427 O
increased 212 221 1428 1437 O
risk 222 226 1438 1442 O
of 227 229 1443 1445 O
lethal 230 236 1446 1452 B-chronic_disease
infections 237 247 1453 1463 I-chronic_disease
when 248 252 1464 1468 O
treated 253 260 1469 1476 O
with 261 265 1477 1481 O
marrow 266 272 1482 1488 B-treatment
- 272 273 1488 1489 I-treatment
suppressive 273 284 1489 1500 I-treatment
therapy 285 292 1501 1508 I-treatment
. 292 293 1508 1509 O
Appropriate 294 305 1510 1521 O
studies 306 313 1522 1529 O
will 314 318 1530 1534 O
be 319 321 1535 1537 O
undertaken 322 332 1538 1548 O
in 333 335 1549 1551 O
participants 336 348 1552 1564 O
receiving 349 358 1565 1574 O
combination 359 370 1575 1586 O
antiretroviral 371 385 1587 1601 O
therapy 386 393 1602 1609 O
when 394 398 1610 1614 O
indicated 399 408 1615 1624 O

Individuals 0 11 1625 1636 O
with 12 16 1637 1641 O
a 17 18 1642 1643 O
history 19 26 1644 1651 O
of 27 29 1652 1654 O
a 30 31 1655 1656 O
different 32 41 1657 1666 O
malignancy 42 52 1667 1677 B-cancer
are 53 56 1678 1681 O
ineligible 57 67 1682 1692 O
except 68 74 1693 1699 O
for 75 78 1700 1703 O
the 79 82 1704 1707 O
following 83 92 1708 1717 O
circumstances 93 106 1718 1731 O
. 106 107 1731 1732 O
Individuals 108 119 1733 1744 O
with 120 124 1745 1749 O
a 125 126 1750 1751 O
history 127 134 1752 1759 O
of 135 137 1760 1762 O
other 138 143 1763 1768 O
malignancies 144 156 1769 1781 B-cancer
are 157 160 1782 1785 O
eligible 161 169 1786 1794 O
if 170 172 1795 1797 O
they 173 177 1798 1802 O
have 178 182 1803 1807 O
been 183 187 1808 1812 O
disease 188 195 1813 1820 O
- 195 196 1820 1821 O
free 196 200 1821 1825 O
for 201 204 1826 1829 O
at 205 207 1830 1832 O
least 208 213 1833 1838 O
5 214 215 1839 1840 B-lower_bound
years 216 221 1841 1846 I-lower_bound
and 222 225 1847 1850 O
are 226 229 1851 1854 O
deemed 230 236 1855 1861 O
by 237 239 1862 1864 O
the 240 243 1865 1868 O
investigator 244 256 1869 1881 O
to 257 259 1882 1884 O
be 260 262 1885 1887 O
at 263 265 1888 1890 O
low 266 269 1891 1894 O
risk 270 274 1895 1899 O
for 275 278 1900 1903 O
recurrence 279 289 1904 1914 O
of 290 292 1915 1917 O
that 293 297 1918 1922 O
malignancy 298 308 1923 1933 O
. 308 309 1933 1934 O
Individuals 310 321 1935 1946 O
with 322 326 1947 1951 O
the 327 330 1952 1955 O
following 331 340 1956 1965 O
cancers 341 348 1966 1973 B-cancer
are 349 352 1974 1977 O
eligible 353 361 1978 1986 O
if 362 364 1987 1989 O
diagnosed 365 374 1990 1999 O
and 375 378 2000 2003 O
treated 379 386 2004 2011 O
within 387 393 2012 2018 O
the 394 397 2019 2022 O
past 398 402 2023 2027 B-upper_bound
5 403 404 2028 2029 I-upper_bound
years 405 410 2030 2035 I-upper_bound
: 410 411 2035 2036 O
cervical 412 420 2037 2045 B-cancer
cancer 421 427 2046 2052 I-cancer
in 428 430 2053 2055 I-cancer
situ 431 435 2056 2060 I-cancer
, 435 436 2060 2061 O
and 437 440 2062 2065 O
basal 441 446 2066 2071 B-cancer
cell 447 451 2072 2076 I-cancer
or 452 454 2077 2079 O
squamous 455 463 2080 2088 B-cancer
cell 464 468 2089 2093 I-cancer
carcinoma 469 478 2094 2103 I-cancer
of 479 481 2104 2106 I-cancer
the 482 485 2107 2110 I-cancer
skin 486 490 2111 2115 I-cancer

Participants 0 12 2116 2128 O
may 13 16 2129 2132 O
not 17 20 2133 2136 O
be 21 23 2137 2139 O
receiving 24 33 2140 2149 O
any 34 37 2150 2153 O
other 38 43 2154 2159 O
investigational 44 59 2160 2175 B-treatment
agents 60 66 2176 2182 I-treatment
targeting 67 76 2183 2192 O
Histiocytosis 77 90 2193 2206 B-chronic_disease

Participants 0 12 2207 2219 O
who 13 16 2220 2223 O
have 17 21 2224 2228 O
had 22 25 2229 2232 O
chemotherapy 26 38 2233 2245 B-treatment
or 39 41 2246 2248 O
radiotherapy 42 54 2249 2261 B-treatment
within 55 61 2262 2268 O
2 62 63 2269 2270 O
weeks 64 69 2271 2276 O
( 70 71 2277 2278 O
6 71 72 2278 2279 B-upper_bound
weeks 73 78 2280 2285 I-upper_bound
for 79 82 2286 2289 O
nitrosoureas 83 95 2290 2302 B-treatment
or 96 98 2303 2305 O
mitomycin 99 108 2306 2315 B-treatment
C 109 110 2316 2317 I-treatment
) 110 111 2317 2318 O
prior 112 117 2319 2324 O
to 118 120 2325 2327 O
entering 121 129 2328 2336 O
the 130 133 2337 2340 O
study 134 139 2341 2346 O
or 140 142 2347 2349 O
those 143 148 2350 2355 O
who 149 152 2356 2359 O
have 153 157 2360 2364 O
not 158 161 2365 2368 O
recovered 162 171 2369 2378 O
from 172 176 2379 2383 O
adverse 177 184 2384 2391 O
events 185 191 2392 2398 O
due 192 195 2399 2402 O
to 196 198 2403 2405 O
agents 199 205 2406 2412 O
administered 206 218 2413 2425 O
more 219 223 2426 2430 O
than 224 228 2431 2435 O
2 229 230 2436 2437 O
weeks 231 236 2438 2443 O
earlier 237 244 2444 2451 O
. 244 245 2451 2452 O
Corticosteroid 246 260 2453 2467 B-treatment
treatment 261 270 2468 2477 I-treatment
is 271 273 2478 2480 O
allowed 274 281 2481 2488 O

Patients 0 8 2489 2497 O
of 9 11 2498 2500 O
all 12 15 2501 2504 O
ages 16 20 2505 2509 B-age
will 21 25 2510 2514 O
be 26 28 2515 2517 O
eligible 29 37 2518 2526 O

Patients 0 8 2527 2535 O
with 9 13 2536 2540 O
a 14 15 2541 2542 O
history 16 23 2543 2550 O
of 24 26 2551 2553 O
prior 27 32 2554 2559 B-treatment
hematopoietic 33 46 2560 2573 I-treatment
stem 47 51 2574 2578 I-treatment
cell 52 56 2579 2583 I-treatment
transplantation 57 72 2584 2599 I-treatment
( 73 74 2600 2601 I-treatment
HSCT 74 78 2601 2605 I-treatment
) 78 79 2605 2606 I-treatment
, 79 80 2606 2607 O
elevated 81 89 2608 2616 O
conjugated 90 100 2617 2627 O
serum 101 106 2628 2633 O
bilirubin 107 116 2634 2643 O
at 117 119 2644 2646 O
study 120 125 2647 2652 O
entry 126 131 2653 2658 O
, 131 132 2658 2659 O
uncontrolled 133 145 2660 2672 O
systemic 146 154 2673 2681 O
fungal 155 161 2682 2688 B-chronic_disease
, 161 162 2688 2689 O
bacterial 163 172 2690 2699 B-chronic_disease
, 172 173 2699 2700 O
or 174 176 2701 2703 O
other 177 182 2704 2709 O
infection 183 192 2710 2719 B-chronic_disease
, 192 193 2719 2720 O
a 194 195 2721 2722 O
history 196 203 2723 2730 O
of 204 206 2731 2733 O
hepatitis 207 216 2734 2743 B-chronic_disease
B 217 218 2744 2745 I-chronic_disease
or 219 221 2746 2748 I-chronic_disease
C 222 223 2749 2750 I-chronic_disease
infection 224 233 2751 2760 I-chronic_disease
or 234 236 2761 2763 O
a 237 238 2764 2765 O
history 239 246 2766 2773 O
of 247 249 2774 2776 O
cirrhosis 250 259 2777 2786 B-chronic_disease

Pediatric 0 9 2787 2796 O
Population 10 20 2797 2807 O
( 21 22 2808 2809 O
patients 22 30 2809 2817 O
< 31 32 2818 2819 O
18 33 35 2820 2822 B-upper_bound
years 36 41 2823 2828 I-upper_bound
): 41 43 2828 2830 O
Creatinine 44 54 2831 2841 B-clinical_variable
within 55 61 2842 2848 O
normal 62 68 2849 2855 O
limits 69 75 2856 2862 O
or 76 78 2863 2865 O
calculated 79 89 2866 2876 B-clinical_variable
creatinine 90 100 2877 2887 I-clinical_variable
clearance 101 110 2888 2897 I-clinical_variable
greater 111 118 2898 2905 O
than 119 123 2906 2910 O
or 124 126 2911 2913 O
equal 127 132 2914 2919 O
to 133 135 2920 2922 O
90 136 138 2923 2925 B-lower_bound
ml 139 141 2926 2928 I-lower_bound
/ 141 142 2928 2929 I-lower_bound
min/1.73 142 150 2929 2937 I-lower_bound
m2 151 153 2938 2940 I-lower_bound
as 154 156 2941 2943 O
calculated 157 167 2944 2954 O
by 168 170 2955 2957 O
the 171 174 2958 2961 O
Schwartz 175 183 2962 2970 O
formula 184 191 2971 2978 O
for 192 195 2979 2982 O
estimated 196 205 2983 2992 B-clinical_variable
glomerular 206 216 2993 3003 I-clinical_variable
filtration 217 227 3004 3014 I-clinical_variable
rate 228 232 3015 3019 I-clinical_variable
( 233 234 3020 3021 I-clinical_variable
GFR 234 237 3021 3024 I-clinical_variable
) 237 238 3024 3025 I-clinical_variable
where 239 244 3026 3031 O
GFR 245 248 3032 3035 O
( 249 250 3036 3037 O
ml 250 252 3037 3039 O
/ 252 253 3039 3040 O
min/1.73 253 261 3040 3048 O
m2 262 264 3049 3051 O
) 264 265 3051 3052 O
= 266 267 3053 3054 O
k 268 269 3055 3056 O
x 270 271 3057 3058 O
Height 272 278 3059 3065 O
( 279 280 3066 3067 O
cm)/serum 280 289 3067 3076 O
creatinine 290 300 3077 3087 I-clinical_variable
( 301 302 3088 3089 O
mg 302 304 3089 3091 O
/ 304 305 3091 3092 O
dl 305 307 3092 3094 O
) 307 308 3094 3095 O
. 308 309 3095 3096 O
k 310 311 3097 3098 O
is 312 314 3099 3101 O
a 315 316 3102 3103 O
proportionality 317 332 3104 3119 O
constant 333 341 3120 3128 O
which 342 347 3129 3134 O
varies 348 354 3135 3141 O
with 355 359 3142 3146 O
age 360 363 3147 3150 B-age
and 364 367 3151 3154 O
is 368 370 3155 3157 O
a 371 372 3158 3159 O
function 373 381 3160 3168 O
of 382 384 3169 3171 O
urinary 385 392 3172 3179 B-clinical_variable
creatinine 393 403 3180 3190 I-clinical_variable
excretion 404 413 3191 3200 O
per 414 417 3201 3204 O
unit 418 422 3205 3209 O
of 423 425 3210 3212 O
body 426 430 3213 3217 O
size 431 435 3218 3222 O
; 435 436 3222 3223 O
0.45 437 441 3224 3228 B-lower_bound
up 442 444 3229 3231 O
to 445 447 3232 3234 O
12 448 450 3235 3237 B-upper_bound
months 451 457 3238 3244 I-upper_bound
of 458 460 3245 3247 O
age 461 464 3248 3251 O
; 464 465 3251 3252 O
0.55 466 470 3253 3257 O
children 471 479 3258 3266 O
and 480 483 3267 3270 O
adolescent 484 494 3271 3281 O
girls 495 500 3282 3287 O
; 500 501 3287 3288 O
and 502 505 3289 3292 O
0.70 506 510 3293 3297 O
adolescent 511 521 3298 3308 O
boys 522 526 3309 3313 O

Performance 0 11 3314 3325 B-clinical_variable
Score 12 17 3326 3331 I-clinical_variable
> 18 19 3332 3333 O
70 20 22 3334 3336 B-lower_bound
% 22 23 3336 3337 I-lower_bound
( 24 25 3338 3339 O
use 25 28 3339 3342 O
Lansky 29 35 3343 3349 B-clinical_variable
score 36 41 3350 3355 I-clinical_variable
for 42 45 3356 3359 O
age 46 49 3360 3363 B-age
< 50 51 3364 3365 O
16 52 54 3366 3368 O
and 55 58 3369 3372 O
Karnofsky 59 68 3373 3382 B-clinical_variable
score 69 74 3383 3388 I-clinical_variable
for 75 78 3389 3392 O
age 79 82 3393 3396 O
= 83 84 3397 3398 O
> 85 86 3399 3400 O
16 86 88 3400 3402 O
) 88 89 3402 3403 O

Platelets 0 9 3404 3413 B-clinical_variable
≥75,000/µL 10 20 3414 3424 O

Pregnant 0 8 3425 3433 B-pregnancy
women 9 14 3434 3439 B-gender
are 15 18 3440 3443 O
excluded 19 27 3444 3452 O
from 28 32 3453 3457 O
this 33 37 3458 3462 O
study 38 43 3463 3468 O
because 44 51 3469 3476 O
clofarabine 52 63 3477 3488 B-treatment
is 64 66 3489 3491 O
a 67 68 3492 3493 O
nucleoside 69 79 3494 3504 O
analog 80 86 3505 3511 O
with 87 91 3512 3516 O
the 92 95 3517 3520 O
potential 96 105 3521 3530 O
for 106 109 3531 3534 O
teratogenic 110 121 3535 3546 O
or 122 124 3547 3549 O
abortifacient 125 138 3550 3563 O
effects 139 146 3564 3571 O
. 146 147 3571 3572 O
Because 148 155 3573 3580 O
there 156 161 3581 3586 O
is 162 164 3587 3589 O
an 165 167 3590 3592 O
unknown 168 175 3593 3600 O
but 176 179 3601 3604 O
potential 180 189 3605 3614 O
risk 190 194 3615 3619 O
of 195 197 3620 3622 O
adverse 198 205 3623 3630 O
events 206 212 3631 3637 O
in 213 215 3638 3640 O
nursing 216 223 3641 3648 O
infants 224 231 3649 3656 O
secondary 232 241 3657 3666 O
to 242 244 3667 3669 O
treatment 245 254 3670 3679 B-treatment
of 255 257 3680 3682 O
the 258 261 3683 3686 O
mother 262 268 3687 3693 O
with 269 273 3694 3698 O
clofarabine 274 285 3699 3710 O
, 285 286 3710 3711 O
breastfeeding 287 300 3712 3725 O
should 301 307 3726 3732 O
be 308 310 3733 3735 O
discontinued 311 323 3736 3748 O
if 324 326 3749 3751 O
the 327 330 3752 3755 O
mother 331 337 3756 3762 O
is 338 340 3763 3765 O
treated 341 348 3766 3773 O
with 349 353 3774 3778 O
clofarabine 354 365 3779 3790 O
. 365 366 3790 3791 O
These 367 372 3792 3797 O
potential 373 382 3798 3807 O
risks 383 388 3808 3813 O
may 389 392 3814 3817 O
also 393 397 3818 3822 O
apply 398 403 3823 3828 O
to 404 406 3829 3831 O
other 407 412 3832 3837 O
agents 413 419 3838 3844 O
used 420 424 3845 3849 O
in 425 427 3850 3852 O
this 428 432 3853 3857 O
study 433 438 3858 3863 O

Prior 0 5 3864 3869 O
diagnosis 6 15 3870 3879 O
of 16 18 3880 3882 O
Langerhans 19 29 3883 3893 B-cancer
Cell 30 34 3894 3898 I-cancer
Histiocytosis 35 48 3899 3912 I-cancer
( 49 50 3913 3914 I-cancer
stratum 50 57 3914 3921 I-cancer
1 58 59 3922 3923 I-cancer
) 59 60 3923 3924 I-cancer
or 61 63 3925 3927 O
LCH 64 67 3928 3931 B-cancer
- 67 68 3931 3932 I-cancer
related 68 75 3932 3939 I-cancer
disorder 76 84 3940 3948 I-cancer
( 85 86 3949 3950 I-cancer
stratum 86 93 3950 3957 I-cancer
2 94 95 3958 3959 I-cancer
) 95 96 3959 3960 I-cancer
established 97 108 3961 3972 O
by 109 111 3973 3975 O
standard 112 120 3976 3984 O
diagnostic 121 131 3985 3995 O
criteria 132 140 3996 4004 O
and 141 144 4005 4008 O
confirmed 145 154 4009 4018 O
histologically 155 169 4019 4033 O

There 0 5 4034 4039 O
is 6 8 4040 4042 O
no 9 11 4043 4045 O
limitation 12 22 4046 4056 O
of 23 25 4057 4059 O
amount 26 32 4060 4066 O
or 33 35 4067 4069 O
the 36 39 4070 4073 O
type 40 44 4074 4078 O
of 45 47 4079 4081 O
prior 48 53 4082 4087 B-treatment
therapy 54 61 4088 4095 I-treatment
or 62 64 4096 4098 O
drugs 65 70 4099 4104 O

Total 0 5 4105 4110 B-clinical_variable
bilirubin 6 15 4111 4120 I-clinical_variable
≤ 16 17 4121 4122 O
2.5x 18 22 4123 4127 B-upper_bound
institutional 23 36 4128 4141 I-upper_bound
upper 37 42 4142 4147 I-upper_bound
limit 43 48 4148 4153 I-upper_bound
of 49 51 4154 4156 I-upper_bound
normal 52 58 4157 4163 I-upper_bound

Uncontrolled 0 12 4164 4176 O
intercurrent 13 25 4177 4189 O
illness 26 33 4190 4197 O
including 34 43 4198 4207 O
, 43 44 4207 4208 O
but 45 48 4209 4212 O
not 49 52 4213 4216 O
limited 53 60 4217 4224 O
to 61 63 4225 4227 O
ongoing 64 71 4228 4235 O
or 72 74 4236 4238 O
active 75 81 4239 4245 B-chronic_disease
infection 82 91 4246 4255 I-chronic_disease
, 91 92 4255 4256 O
symptomatic 93 104 4257 4268 O
congestive 105 115 4269 4279 B-chronic_disease
heart 116 121 4280 4285 I-chronic_disease
failure 122 129 4286 4293 I-chronic_disease
, 129 130 4293 4294 O
unstable 131 139 4295 4303 B-chronic_disease
angina 140 146 4304 4310 I-chronic_disease
pectoris 147 155 4311 4319 O
, 155 156 4319 4320 O
cardiac 157 164 4321 4328 B-chronic_disease
arrhythmia 165 175 4329 4339 I-chronic_disease
, 175 176 4339 4340 O
or 177 179 4341 4343 O
psychiatric 180 191 4344 4355 B-chronic_disease
illness 192 199 4356 4363 I-chronic_disease
/ 199 200 4363 4364 O
social 200 206 4364 4370 O
situations 207 217 4371 4381 O
that 218 222 4382 4386 O
would 223 228 4387 4392 O
limit 229 234 4393 4398 O
compliance 235 245 4399 4409 O
with 246 250 4410 4414 O
study 251 256 4415 4420 O
requirements 257 269 4421 4433 O

Use 0 3 4434 4437 O
of 4 6 4438 4440 O
alternative 7 18 4441 4452 O
medications 19 30 4453 4464 O
( 31 32 4465 4466 O
e.g. 32 36 4466 4470 O
, 36 37 4470 4471 O
herbal 38 44 4472 4478 B-treatment
or 45 47 4479 4481 O
botanical 48 57 4482 4491 B-treatment
that 58 62 4492 4496 O
could 63 68 4497 4502 O
interfere 69 78 4503 4512 O
with 79 83 4513 4517 O
clofarabine 84 95 4518 4529 B-treatment
) 95 96 4529 4530 O
is 97 99 4531 4533 O
not 100 103 4534 4537 O
permitted 104 113 4538 4547 O
during 114 120 4548 4554 O
the 121 124 4555 4558 O
entire 125 131 4559 4565 O
study 132 137 4566 4571 O
period 138 144 4572 4578 O

